JSAM
OLMA icon

J. Safra Asset Management’s Olema Pharmaceuticals OLMA Stock Holding History

J. Safra Asset Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.99K Buy
559
+286
+105% +$3.83K ﹤0.01% 443
2026
Q1 		$4.07K Buy
+273
New +$6.08K ﹤0.01% 507

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

J. Safra Asset Management's OLMA Position: Q2 2026 in Review

J. Safra Asset Management increased its Olema Pharmaceuticals (OLMA) stake by 105% in Q2 2026, buying an estimated $3.83K and bringing the position to 559 shares worth $6.99K. The position accounts for ﹤0.01% of the portfolio, ranked #443.

J. Safra Asset Management first reported a position in OLMA in Q1 2026 and has held it in 2 quarters since. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • J. Safra Asset Management held 559 shares of Olema Pharmaceuticals worth $6.99K as of Q2 2026.
  • J. Safra Asset Management bought 286 Olema Pharmaceuticals shares in Q2 2026, an estimated $3.83K.
  • Olema Pharmaceuticals made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #443 holding.
  • J. Safra Asset Management first reported a position in Olema Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.